Apollo Hospitals Enterprise stock
APOLLOHOSP.NSNSEApollo Hospitals Enterprise Limited, HealthcareISIN INE437A01024
70Score 70 out of 100, Strong
Price and trend
72 / 100
Price history
+14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 4.4% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 6.1% below its 52-week high. Largest decline in 20 years: 40% (January 2008 to March 2009).
Chart figures for advanced users
- SMA 50$89.41
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$87.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$72.51
- The lowest closing price of the last twelve months.
- Resistance$96.79
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Apollo Hospitals Enterprise Limited belongs to the Medical (Care Facilities) industry (India) and, with a market value of $13.07B, is number 6 of 56 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $2.69B (up 15.8% year on year) and earnings of $207.24M (up 34.3%).
- For fiscal 2027, analysts expect on average revenue of $3.21B (up 19.1%) and adjusted earnings per share of $1.83 (up 25.9%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 130 of 714 in Healthcare, median 53.
- The P/E is 54.6 (Medical (Care Facilities) median 54.9, own median of recent years 73.4).
- Our model puts fair value at $84.93, with the price 8% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 65.9% a year since 2021.Growth 76
- Growing faster than its industryRevenue up 19% a year since 2021, Healthcare sector median 12%.Growth 76
- Analysts expect strong earnings growthUp 24% a year through 2029 (estimates from 25 analysts).Growth 76
Weaknesses
- Margin fallingOperating margin 11.5%, average of the prior years 29.3% (to 2025).
Its standout strengths are capital allocation and growth, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $70.77 and expensive above $106.16 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $78.61 (cash-flow model) and $91.25 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $78.25, at 11.6% it would be $94.53.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (54.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 19.2% on the twelve months before. Revenue has grown strongly since 2007, at around 19% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 33%, operating 11%, net 8%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 5 Feb 2027in 85 days
- Last reported
- 4 Nov 2026EPS reported $0.47 (expected $0.46)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 26 Oct 2026.
- Earnings per share
- $1.83−0.3%
- Revenue
- $3.21B0.0%
- Earnings per share
- $2.33−0.6%
- Revenue
- $3.84B+0.1%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Apollo Hospitals Enterprise
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Fresenius SE & Co. KGaAFRE.DE $33.1B57
- Tenet HealthcareTHC $23.32B76
- Encompass HealthEHC $13.96B75
- Rede D'Or São LuizRDOR3.SA $13.45B62
- Aier Eye Hospital Group300015.SZ $12.08B66
- Fresenius Medical Care AG & Co. KGaAFME.DE $11.78B59
- Universal Health ServicesUHS $11.57B73
- DaVitaDVA $11.54B67
ETFs that hold Apollo Hospitals Enterprise
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.63% | 0.65% | €4.91B |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.43% | 0.60% | €31.52M |
| iShares Edge MSCI EM Minimum Volatility UCITS ETFEUNZ | 0.39% | 0.40% | €428.84M |
Show 5 more
| iShares MSCI EM Asia UCITS ETFCEBL | 0.10% | 0.20% | €6.97B |
| iShares MSCI EM UCITS ETF USD (Dist)IQQE | 0.08% | 0.18% | €8.33B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.08% | 0.18% | €37.17B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.07% | 0.18% | €5.15B |
| iShares MSCI EM CTB Enhanced ESG UCITS ETFEDM2 | 0.02% | 0.18% | €7.09B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ₹93.6946)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.